BioPharma Dive March 17, 2025
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for its lead candidate.
Latigo Biotherapeutics, a private drug company developing experimental pain medicines, has closed another nine-figure fundraising round.
Asset manager Blue Owl Capital led the $150 million Series B round. As part of the raise, Kevin Raidy, a senior managing director at Blue Owl, has joined Latigo’s board of directors. More than half a dozen other new backers participated in the financing, as did existing investors 5AM Ventures, Foresite Capital, Alexandria Venture Investments and the firm that created Latigo, Westlake Village BioPartners.
Latigo’s research mostly focuses on NaV1.8, a tube-shaped protein embedded in the outer casings of cells....
Today's Sponsors
Today's Sponsor